← Back to Search

Anti-metabolites

Combination Chemotherapy + IM-862 for Ovarian Cancer

Phase 2
Waitlist Available
Research Sponsored by Cytran
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed stage III ovarian epithelial cancer or primary peritoneal carcinoma of specified cell types
Underwent prior standard initial cytoreductive surgery within the past 6 weeks
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying IM-862 to see how well it works in combination with standard chemotherapy in treating patients with ovarian or primary peritoneal cancer.

Who is the study for?
This trial is for adults over 18 with stage III ovarian or primary peritoneal cancer, who've had successful surgery recently. They shouldn't have other cancers (except certain skin/breast/cervical cancers) in the past 5 years, no major illnesses, and not be on experimental drugs within the last year. Their liver and kidney functions must meet specific criteria.Check my eligibility
What is being tested?
The study tests if combining chemotherapy with a drug called IM-862 improves outcomes in patients after surgery for ovarian or primary peritoneal cancer. It's a phase II trial where participants are randomly assigned to receive this combination treatment to see its effectiveness.See study design
What are the potential side effects?
Chemotherapy can cause side effects like nausea, fatigue, hair loss, increased risk of infection due to low blood cell counts. IM-862 might lead to reduced blood flow to tumors which could affect nearby tissues/organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have stage III ovarian or primary peritoneal cancer.
Select...
I had surgery to reduce my tumor size within the last 6 weeks.
Select...
My surgery removed the cancer well, leaving no large remaining tumors.
Select...
All my cancer outside the reproductive tract has been removed.
Select...
My liver function tests are within normal ranges.
Select...
My kidney function tests are within normal ranges.
Select...
I haven't had any other cancer in the last 5 years.
Select...
I am 18 years old or older.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I have had surgery to remove my uterus, ovaries, and fallopian tubes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

CytranLead Sponsor
1 Previous Clinical Trials
200 Total Patients Enrolled
Pamela Paley, MDStudy ChairPacific Gynecology Specialists
2 Previous Clinical Trials
657 Total Patients Enrolled

Media Library

Combination Chemotherapy (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00017303 — Phase 2
Ovarian Cancer Research Study Groups:
Ovarian Cancer Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00017303 — Phase 2
Combination Chemotherapy (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00017303 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the risks associated with this type of care?

"While there is data supporting the safety of this intervention, it is only from a Phase 2 trial, so Power rates its safety as a 2."

Answered by AI

Are people still being recruited for this experiment?

"Unfortunately, this study is no longer recruiting patients. Although the last update was on November 5th 2013, it was originally posted on January 1st 2001. There are however 703 other clinical trials that are actively looking for participants."

Answered by AI

In how many distinct places is this research being conducted?

"Right now, this trial has 19 sites where patients can be enrolled. If you are interested in enrolling, try to select a site that is close to your location to minimize travel time and costs. The locations include Saint Louis, Madison, Omaha and 16 other cities."

Answered by AI
~14 spots leftby Mar 2025